DataMeds AI, Inc. (MEDS) · Nov 20, 2026 · Other events
$5,450 insider purchase — 5,000 shares at $1.09 per share
DataMeds AI disclosed a small insider stock purchase by its co-CEO. It signals confidence during the company’s healthcare-tech transition, but adds no operating news.
DataMeds AI is transitioning from its Wellgistics-era pharmacy and pharmaceutical-logistics operations toward a broader healthcare-technology and AI strategy, while also pursuing new financing and strategic transactions. The filing adds a confidence signal, not an operating development. Co-CEO Gerald Commissiong bought 5,000 shares at $1.09, or roughly $5,450 in total. That is directionally supportive, but too small to materially change the company’s financing position, execution outlook, or still-developing strategic story.
Bottom line: This is a modest insider-confidence signal during a complicated transition, but it does not materially change the business case or the market’s core expectations.**
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!